Sequential Skin: Revolutionising atopic dermatitis diagnosis through a novel skin microbiome test.

特应性皮炎（AD）是一种多因素慢性和复发性炎症性皮肤病，影响五分之一的英国儿童和十分之一的成年人。大约29%是中度/重度病例，仅在英国就影响了197万患者，每年的医疗保健和社会经济成本超过7.23亿英镑。由于没有明确的治愈方法，控制阿尔茨海默病突发/进展的重大治疗挑战来自：*不同阿尔茨海默病/发病机制的复杂性*许多不同的患者群体*超过1000种潜在的治疗途径跨越不同的治疗和配方。然而，现有的诊断方法有效地告知/靶向这些现有治疗的能力有限。此外，虽然最近的研究表明，患者的皮肤微生物组可以决定疾病的进展，但目前还没有实用的临床工具来精确分析皮肤微生物组，这阻碍了对新兴的个性化阿尔茨海默病药物/治疗进行患者分层。因此，治疗途径（NHS/私人）是多次就诊的反复试验，未能充分：*缓解症状*尽量减少副作用*减缓疾病进展。序列皮肤有限公司已经推出了一种颠覆性的消费者皮肤测试，用于美容皮肤健康应用，基于专有的：*关键细菌微生物组标记分析，以及基因测序*非侵入性皮肤取样贴片，与其他直接面向消费者的基因检测公司相比，实验室流程将皮肤分子结果的时间缩短了75%。利用突破性研究证明，使用微生物DNA生物标记物集群可以改善AD进展的预测，Sequential skin现在的目标是将这些发展扩展到临床领域。目标是针对患者特异性AD分析和治疗预后的第一个非侵入性临床生物信息学解决方案。

Atopic dermatitis (AD) is a multifactorial chronic and recurrent inflammatory skin disease, affecting 1-in-5 UK children and 1-in-10 adults. Circa.29% are moderate/severe cases -- affecting over 1.97million patients in the UK alone -- with healthcare and socio-economic costs exceeding £723million annually.With no definitive cure, a significant therapeutic challenge to manage AD flare-ups/progression arises from:* Complexity across varied AD conditions/pathogeneses* Many disparate patient populations* Over 1000 potential therapeutic pathways across different treatments and formulationsHowever, capability of incumbent diagnostic approaches to effectively inform/target these existing treatments is limited.Furthermore, whilst recent research demonstrates that patients' skin microbiome can dictate disease progression, no practical clinical tool for precision skin microbiome analysis exists, preventing patient stratification for emerging personalised AD medicines/treatments.Consequently, treatment pathways (NHS/private) are trial-and-error over multiple visits, failing to adequately:* Relieve symptoms* Minimise side effects* Mitigate disease progression.Sequential Skin Ltd have already introduced a disruptive consumer skin-test for cosmetic skin health applications, based on proprietary:* Analysis of key bacterial microbiome-markers, alongside genetic sequencing* Patches for non-invasive skin sampling, already achieving significantly higher collection efficiency than existing swabs and tape-stripping gold-standards* Laboratory processes reducing time-around for skin molecular results by 75% with respect to other direct-to-consumer genetic testing companiesLeveraging breakthrough research demonstrating improved prediction of AD progression using microbial DNA biomarker clusters, Sequential Skin now aim to extend these developments into the clinical domain, targeting the first non-invasive clinical bioinformatic solution for patient-specific AD profiling and treatment prognosis.